Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Profhilo Haenkenium is a topical antioxidant and hydrating cream developed by IBSA Farmaceutici. It features a synergistic combination of a dual-molecular-weight hyaluronic acid complex (containing both high and low molecular weight sodium hyaluronate) and Haenkenium, a patented extract from *Salvia haenkei*. The Haenkenium component acts as a potent antioxidant that protects skin cells from oxidative stress and premature cellular senescence while inhibiting the enzymatic degradation of hyaluronic acid. The hyaluronic acid complex provides deep hydration and supports the skin's hydrolipidic film and extracellular matrix. While primarily marketed as a cosmeceutical for skin rejuvenation and anti-aging, it is also being investigated in clinical trials for the treatment of atopic dermatitis symptoms in adults.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Profhilo Haenkenium.